The phase 3 NRG Oncology GU005 trial tested SBRT vs MH-IMRT radiation for intermediate-risk prostate cancer for disease control and quality of life.

A randomized trial compared short-term androgen deprivation with high-dose radiotherapy (STADT-RT) and high-dose radiation therapy alone in localized prostate cancer.

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...

Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...

For patients with intermediate-risk localized prostate cancer, stereotactic body radiation therapy (SBRT) yields favorable bowel health-related quality of life (HRQOL).

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced ...